Erratum: Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High Throughput 'Unbiased' Screening Campaign (J. Med. Chem. (2021) 64:9 (5577−5592) DOI: 10.1021/acs.jmedchem.0c02041)

For the described pyrrolidine bis-cyclic guanidine compounds, the correct starting reagents and synthetic methodologies were described. During the reduction of the amide moieties to amines (see Scheme 1 as a representative example), Cahn-Ingold- Prolog sequence rules dictate that the a-carbon of R3 DThr residues (found in compounds 1, 2, 3, 10, 11, 12, 19, 20, 21, 28, 29, and 30) switches from R to S. The -carbon on the side chain is not reprioritized following the reduction and remains S. While the a-carbon was correctly labeled in the publication, the -carbon was inadvertently switched to R. Therefore, the R3 position of compounds 1, 2, 3, 10, 11, 12, 19, 20, 21, 28, 29, and 30 should read (S,S)-1-hydroxyethyl, not (S,R)-. A complete, corrected Table 1 is presented below. In the Supporting Information, the compound titles in the compound characterization section and SMILES structures for 1, 2, 3, 10, 11, 12, 19, 20, 21, 28, 29, and 30 are incorrect. As an example, the title for 1 should be (S)-1-((S)-3-(adamantan-1-ylmethyl)-1- ((R)-1-cyclohexyl-3-((S)-2-(((R)-2-imino-5-isobutylimidazolidin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-iminoimidazolidin-4- yl)ethanol, not the reported (R)-1-((S)-3-(adamantan-1-ylmethyl)- 1-((R)-1-cyclohexyl-3-((S)-2-(((R)-2-imino-5-isobutylimidazoli-din-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-iminoimidazolidin-4-yl)ethanol. The authors apologize for the error. {table presented} {figure presented}.